13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • I3Y-MC-JPCP

    Acronym: 

    I3Y-MC-JPCP

    ACTRN/NCT /ethics: 

    NCT03703466

    Scientific title: 

    A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II Tumour Stream Breast
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date 2018-11-28
    Molecular Target Anticipated End Date 2021-02-20
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Breast
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2018-11-28
    Anticipated End Date 2021-02-20

    Trial Summary

    The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.

    Lay Summary

    A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

    Sponsor / Cooperative group

    Eli Lilly

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Completed